PMID- 34064866
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210615
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 13
IP  - 5
DP  - 2021 May 11
TI  - Twenty Years of Research on Cyclodextrin Conjugates with PAMAM Dendrimers.
LID - 10.3390/pharmaceutics13050697 [doi]
LID - 697
AB  - Recently, the number of gene and oligonucleotide drugs are increasing. Of various 
      drug delivery systems (DDSs) for gene and oligonucleotide drugs, few examples of 
      the clinical application of polymer as drug carriers are known, despite 
      development of the novel polymers has been progressing. Cyclodextrin (CD) 
      conjugates with starburst polyamidoamine (PAMAM) dendrimer (CDEs), as a new type 
      of polymer-based carriers, were first published in 2001. After that, galactose-, 
      lactose-, mannose-, fucose-, folate-, and polyethyleneglycol (PEG)-appended CDEs 
      have been prepared for passive and active targeting for gene, oligonucleotide, 
      and low-molecular-weight drugs. PEG-appended CDE formed polypsuedorotaxanes with 
      alpha-CD and gamma-CD, which are useful for a sustained release system of gene and 
      oligonucleotide drugs. Interestingly, CDEs were found to have anti-inflammatory 
      effects and anti-amyloid effects themselves, which have potential as active 
      pharmaceutical ingredients. Most recently, CDE is reported to be a useful 
      Cas9-RNA ribonucleoproteins (Cas9 RNP) carrier that induces genome editing in the 
      neuron and brain. In this review, the history and progression of CDEs are 
      overviewed.
FAU - Arima, Hidetoshi
AU  - Arima H
AD  - School of Pharmacy, Daiichi University of Pharmacy, Fukuoka 815-8511, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210511
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC8151880
OTO - NOTNLM
OT  - anti-amyloid effect
OT  - anti-inflammatory effect
OT  - antitumor drugs
OT  - conjugate
OT  - cyclodextrin
OT  - dendrimer
OT  - gene
OT  - oligonucleotide
OT  - polyamidoamine
OT  - polypseudorotaxane
COIS- The author declares no conflict of interest.
EDAT- 2021/06/03 06:00
MHDA- 2021/06/03 06:01
PMCR- 2021/05/11
CRDT- 2021/06/02 01:11
PHST- 2021/03/05 00:00 [received]
PHST- 2021/05/03 00:00 [revised]
PHST- 2021/05/04 00:00 [accepted]
PHST- 2021/06/02 01:11 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/03 06:01 [medline]
PHST- 2021/05/11 00:00 [pmc-release]
AID - pharmaceutics13050697 [pii]
AID - pharmaceutics-13-00697 [pii]
AID - 10.3390/pharmaceutics13050697 [doi]
PST - epublish
SO  - Pharmaceutics. 2021 May 11;13(5):697. doi: 10.3390/pharmaceutics13050697.